Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Rhea-AI Summary

Cyteir Therapeutics, Inc. (NASDAQ: CYT) announced that its President and CEO, Markus Renschler, MD, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 8:35 AM EDT. The event will be available via live webcast on Cyteir's website, with a replay accessible for 30 days post-event. Cyteir focuses on developing next-generation synthetically lethal therapies for cancer, with its lead compound, CYT-0851, currently in Phase 1/2 clinical trials for various malignancies.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022.

Morgan Stanley 20th Annual Global Healthcare Conference
Date: Wednesday, September 14
Time: 8:35 AM EDT

A live webcast will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. At Cyteir, we employ an integrated target discovery approach that incorporates a critical evaluation of the target biology with internal and external information from a variety of genetic and chemical synthetic lethality screens to fuel our drug discovery and development pipeline. Cyteir’s wholly owned lead compound, CYT-0851, is a selective oral investigational drug currently in a Phase 1/2 clinical trial for hematologic malignancies and solid tumors. Follow Cyteir on social media: LinkedIn and Twitter and at www.cyteir.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005133/en/

Lisa Hayes

Vice President, Investor Relations and Corporate Communications

908-868-8926

Lisa.Hayes@cyteir.com

Source: Cyteir Therapeutics

FAQ

When is Cyteir Therapeutics participating in the Morgan Stanley Healthcare Conference?

Cyteir Therapeutics will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022.

What time will Cyteir's fireside chat occur at the conference?

The fireside chat will take place at 8:35 AM EDT.

Where can I watch the live webcast of Cyteir's conference participation?

The live webcast can be viewed in the Investors & Media section of Cyteir's website.

What is the focus of Cyteir Therapeutics?

Cyteir Therapeutics focuses on the discovery and development of next-generation synthetically lethal therapies for cancer.

What is the investigational drug CYT-0851 used for?

CYT-0851 is being evaluated in Phase 1/2 clinical trials for treating hematologic malignancies and solid tumors.